Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor Corporation (NASDAQ:DXR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael Richard Feldschuh CEO | NASDAQ (CM) Exchange | 239467103 CUSIP |
| US Country | 37 Employees | 12 Jan 2018 Last Dividend | - Last Split | 17 Mar 1992 IPO Date |
Daxor Corporation is an innovative medical device company specializing in the advancement of blood volume measurement technology. Pivotal to its operations is the focus on developing and providing a diagnostic blood test known as BVA-100 Blood Volume Analyzer. This proprietary technology is centered around delivering safe, accurate, and objective quantification of a patient's blood volume status and composition, benchmarked against patient-specific norms. The ability to precisely determine blood volume is critical across a myriad of medical and surgical conditions, thereby underscoring the importance of Daxor's contributions to the healthcare sector. Originally established as Idant Corporation, the company underwent a rebranding to Daxor Corporation in May 1973, marking a significant milestone in its corporate evolution. With its roots tracing back to 1971, Daxor Corporation is strategically headquartered in Oak Ridge, Tennessee, from where it continues to innovate and impact the medical community.
Daxor's flagship product, the BVA-100 Blood Volume Analyzer, represents a groundbreaking approach to blood volume analysis. This diagnostic tool is engineered to provide an accurate and objective measurement of a patient's blood volume status and composition relative to individual-specific norms. The technology's precision and safety make it an invaluable resource for clinicians across various medical and surgical specialties seeking to diagnose and manage conditions related to blood volume imbalances.